Hypera S.A. (OTCMKTS:HYPMY – Get Free Report)’s stock price hit a new 52-week low during mid-day trading on Tuesday . The stock traded as low as $4.74 and last traded at $5.01, with a volume of 5991 shares. The stock had previously closed at $4.88.
Hypera Stock Performance
The firm has a fifty day simple moving average of $5.22 and a 200 day simple moving average of $5.61. The company has a market capitalization of $3.17 billion, a PE ratio of 9.69 and a beta of 1.04.
Hypera (OTCMKTS:HYPMY – Get Free Report) last released its quarterly earnings data on Thursday, July 25th. The company reported $0.15 earnings per share for the quarter. The business had revenue of $420.00 million during the quarter.
About Hypera
Hypera SA operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, Max Sulid, milgamma, Mioflex A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands.
See Also
- Five stocks we like better than Hypera
- Investing in Travel Stocks Benefits
- Biohaven Stock Soars on Drug Trial Results: Time to Jump In?
- How to Calculate Return on Investment (ROI)
- Is AMD a Legitimate Threat to NVIDIA? What Investors Should Watch
- What is an Earnings Surprise?
- Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
Receive News & Ratings for Hypera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hypera and related companies with MarketBeat.com's FREE daily email newsletter.
